{"id":1356,"date":"2023-01-05T00:07:29","date_gmt":"2023-01-05T00:07:29","guid":{"rendered":"https:\/\/mpsdsehcp-dev-001.azurewebsites.net\/en\/mucopolysaccharidosis-mps\/?page_id=1356"},"modified":"2023-12-04T09:16:17","modified_gmt":"2023-12-04T09:16:17","slug":"types-of-mps","status":"publish","type":"page","link":"https:\/\/hcp.biomarin.com\/en-gb\/mps\/types-of-mps\/","title":{"rendered":"Types of MPS"},"content":{"rendered":"
\n
<\/div>\n\t
<\/div>\n \t
<\/div>\n\t
\n\t\t
\n\t\t\t
\n\t\t\t \t\t\t\t\t\t\t\t\t\t\t\t

Types of MPS\n<\/h1>\n\t\t\t\t\t\t\t\t\t\t\t\t

Multisystemic, unpredictable and life threatening<\/p>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n<\/div>\n\n\n

\n
\n
\n \n
\n

Variability in disease progression and presentation often delays diagnosis, making early intervention critical1<\/sup><\/h2>\n

While each subtype of MPS disorder is clinically distinct, all feature the life-limiting, progressive, multisystemic disease manifestations common to MPS disease pathology.2,3,4,5<\/sup> Management of patients with MPS requires an understanding of the specific clinical manifestations and management recommendations for each MPS subtype.2,6<\/sup><\/p>\n <\/div>\n <\/div>\n <\/div>\n<\/div>\n\n

\n
\n
\n \n
\n

MPS I<\/h2>\n

Disease name: Hurler, Hurler\/Scheie, Scheie<\/strong> | Deficient enzyme: \u03b1-L-iduronidase<\/strong> | Gene symbol: IDUA<\/em><\/strong><\/p>\n

Patients with Mucopolysaccharidosis Type I (MPS I) are at increased risk for severe morbidity and early mortality1<\/sup><\/h3>\n

MPS I is a progressive condition2<\/sup> that has been divided into 3 subtypes known as Hurler syndrome (MPS I-H), Hurler-Scheie syndrome (MPS I-H\/S), and Scheie syndrome (MPS I-S).3<\/sup> All subtypes of MPS I are caused by a deficiency of the enzyme \u03b1-L-iduronidase, which is required for the degradation of the glycosaminoglycans (GAGs) heparan sulphate and dermatan sulphate,2,4<\/sup> with resulting progressive, multisystemic manifestations.2<\/sup><\/p>\n